Pneumocystis carinii pneumonitis was prevented in 0, 50, 100, and 100% of immunosuppressed rats given doses of 0.5, 5.0, 25.0, and 125.0 mg/kg (body weight) per day, respectively, of 4,4'-sulfonylbisformanilide (DFD). Therapeutic efficacy was demonstrated with DFD at 25.0 mg/kg per day, and when this dose was combined with trimethoprim, the combination was as effective as trimethoprim-sulfamethoxazole, which has been proven to be effective in the treatment of murine and human P. carinnu pneumonitis.
Recently, we found diaminodiphenylsulfone (dapsone) to be highly effective in the treatment and prevention of murine Pneumocystis carinii pneumonitis (6) . Subsequently, two clinical studies in patients with acquired immunodeficiency syndrome showed dapsone in combination with trimethoprim (TMP) to be highly effective in the treatment of P. carinii pneumonitis (G. S. Leoung s7-4, 1985) . Whereas some patients had adverse reactions to dapsone, others with and without intolerance to TMP-sulfamethoxazole (SMZ) were able to take dapsone uneventfully.
The purpose of this study was to evaluate the diformyl derivative of dapsone, 4,4'-sulfonylbisformanilide (DFD), for its anti-P. carinii effect. DFD is deformylated rapidly in the plasma (4) and liver (2) to diaminodiphenylsulfone. DFD has been found to exhibit a greater antimalarial activity in mice, on a weight basis, than dapsone (1) and to protect human voluntee-rs challenged with Plasmodium falciparum (3) . Also, tolerance studies in humans showed that escalating single doses up to 4,800 mg do not produce objective evidence of toxicity, suggesting a greater degree of safety than with dapsone.
When rats are immunosuppressed with dexamethasone for 6 weeks or longer and protected from bacterial infection by the administration of antibiotics, from 90 to 100% develop P. carinii pneumonitis that is easily demonstrated at autopsy. This animal model has been used previously for the study of dapsone and other antimicrobial agents in this infection (6) . Drugs administered during the period of immunosuppression can be evaluated for anti-P. carinii activity by examination of the lung histologically at a point when a high proportion of the untreated controls are heavily infected with the organism. DFD was evaluated in this system by using the same experimnental plan as described previously for the study of dapsone (6) .
Four dose levels of DFD were studied. Doses of 0.5, 5.0, 25.0, and 125.0 mg/kg (body weight) per day were added to the daily food supply. DFD was obtained from the Jacobus Pharmaceutical Co., Inc., Princeton, N.J. It was tested in combination with TMP dapsone would likely stem from its lower toxicity and fewer side effects, if any. In a report by Heymann and Fieser (5), mention was made of Maier's findings that DFD is as effective as dapsone in the treatment of the avian form of malaria but DFD is less toxic.
Hemolysis and methemoglobin formation are two major side effects of dapsone administration which limit its utility. Kiese (7) and Weisburger and Weisburger (9) reviewed the mechanism of hemolysis and methemoglobin reduction. Sonntag et al. (8) reported preliminary data in dogs which support the suggestion that intravenous DFD produces less methemoglobin than does dapsone. They also reported that 90% of intravenous DFD is converted to dapsone in 9 h.
Human volunteer studies have provided information on the pharmacokinetics of DFD (8) . After a single oral dose of 1,600 mg (estimated as 23 mg/kg for a 70-kg man), the maximum levels in plasma were 2.9 ± 0.6 ,ug/ml at 5 to 8 h with a half-life of 24 to 36 h. DFD is rapidly metabolized to yield dapsone. However, these workers also reported that DFD by mnouth in malarial prophylaxis studies is poorly absorbed and suggested that DFD be given at least two to three times per week if levels in plasma greater than 0.5 pLg/ml are to be maintained. No data are available for levels in the serum of rats given DFD orally. It cannot be assumed that levels in serum with the 23-mg/kg dosage mentioned above for man would be similar to those for the 25 mg/kg per day used in our rat study, because wide variations in drug levels may occur from one animal species to another.
DFD presents some problems in oral bioavailability, but it might be a better tolerated form than dapsone for parenteral administration. However, adequate human trials comparing DFD and dapsone have not been done. Maurizio Strosselli provided technical assistance.
